Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock

ConditionCardiogenic Shock

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorCMC Ambroise Paré

About this trial

Cardiogenic shock is a life-threatening condition characterized by inadequate cardiac output, leading to organ hypoperfusion and high mortality. Maintaining mean arterial pressure (MAP) is crucial, but standard targets may be insufficient due to venous congestion. Central venous pressure (CVP) can help assess effective perfusion pressure. This study investigates whether a personalized MAP target adjusted by CVP improves organ function and survival compared to standard MAP management.

Eligibility criteria

Qualifiers

Aged ≥18 years

Cardiogenic shock state, according to the consensus definition,

SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C

Consent from the patient or close relative / trusted person or emergency inclusion procedure

Disqualifiers

Catecholamine infusion for more than 24 consecutive hours;

CVP < 5 mm Hg at inclusion;

MAP > 70 mmHg at inclusion;

Chronic kidney disease stage G4 (defined by an eGFR between 15-29 ml/min/1.73 m²) or G5 (defined by an eGFR less than 15 ml/min/1.73 m²) according to the KDIGO CKD classification at inclusion;

Trial design

Treatments tested in this trial

Personalized MAP
Standard MAP

Treatment groups

406 Participants

are divided into 2 treatment groups

Sponsors and collaborators

CMC Ambroise Paré

Lead sponsor

Source ClinicalTrials.gov